MXPA06004498A - Compuestos de pirimidina para el tratamiento de inflamacion. - Google Patents
Compuestos de pirimidina para el tratamiento de inflamacion.Info
- Publication number
- MXPA06004498A MXPA06004498A MXPA06004498A MXPA06004498A MXPA06004498A MX PA06004498 A MXPA06004498 A MX PA06004498A MX PA06004498 A MXPA06004498 A MX PA06004498A MX PA06004498 A MXPA06004498 A MX PA06004498A MX PA06004498 A MXPA06004498 A MX PA06004498A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- group
- heteroaryl
- methyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51377003P | 2003-10-23 | 2003-10-23 | |
PCT/IB2004/003314 WO2005040133A1 (fr) | 2003-10-23 | 2004-10-11 | Composes de pyrimidine utiles pour le traitement des inflammations |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06004498A true MXPA06004498A (es) | 2006-06-20 |
Family
ID=34520134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06004498A MXPA06004498A (es) | 2003-10-23 | 2004-10-11 | Compuestos de pirimidina para el tratamiento de inflamacion. |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1678146A1 (fr) |
JP (1) | JP2007509126A (fr) |
BR (1) | BRPI0415678A (fr) |
CA (1) | CA2542514A1 (fr) |
MX (1) | MXPA06004498A (fr) |
WO (1) | WO2005040133A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
DE102005025225A1 (de) | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
JP2011032169A (ja) * | 2007-12-11 | 2011-02-17 | Genecare Research Institute Co Ltd | 4−アミノピリミジン誘導体および該化合物を含有する医薬組成物 |
DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
RU2012131341A (ru) | 2009-12-23 | 2014-01-27 | Санофи | Индол-пиперидинилбензиламины как ингибиторы бета-триптазы |
BR112013015449A2 (pt) | 2010-12-21 | 2016-09-20 | Novartis Ag | compostos de bi-heteroarila como inibidores de vps23 |
WO2017088755A1 (fr) * | 2015-11-23 | 2017-06-01 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Composé aminopyrimidine hétérocyclique présentant une activité antagoniste du récepteur de l'adénosine |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
EP3759109B1 (fr) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD236310A1 (de) * | 1984-08-23 | 1986-06-04 | Univ Leipzig | Verfahren zur herstellung von 2,6-diarylsubstituierten 4-arylamino-pyrimidin-5-carbonsaeureestern |
JP2001089452A (ja) * | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
US6869956B2 (en) * | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
JP4359146B2 (ja) * | 2002-02-13 | 2009-11-04 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なピリジン−およびピリミジン−誘導体 |
GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
-
2004
- 2004-10-11 JP JP2006536194A patent/JP2007509126A/ja not_active Withdrawn
- 2004-10-11 BR BRPI0415678-1A patent/BRPI0415678A/pt not_active Application Discontinuation
- 2004-10-11 MX MXPA06004498A patent/MXPA06004498A/es unknown
- 2004-10-11 CA CA002542514A patent/CA2542514A1/fr not_active Abandoned
- 2004-10-11 WO PCT/IB2004/003314 patent/WO2005040133A1/fr not_active Application Discontinuation
- 2004-10-11 EP EP04769607A patent/EP1678146A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BRPI0415678A (pt) | 2006-12-19 |
JP2007509126A (ja) | 2007-04-12 |
WO2005040133A1 (fr) | 2005-05-06 |
CA2542514A1 (fr) | 2005-05-06 |
EP1678146A1 (fr) | 2006-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050197338A1 (en) | Substituted pyrazole urea compounds for the treatment of inflammation | |
KR100835265B1 (ko) | 산화 질소 신타아제 억제제로 유용한 아미디노 화합물 및그들의 염 | |
WO2005105777A1 (fr) | Composes d'amide a substitution de thiophene pour le traitement de l'inflammation. | |
JP3256526B2 (ja) | 抗炎症および鎮痛剤としての置換インドール化合物 | |
JP2004512271A (ja) | 誘導型一酸化窒素シンターゼ阻害薬としてのヘキサヒドロ−7−1h−アゼピン−2−イル−ヘキサン酸誘導体 | |
JP3962425B2 (ja) | 炎症治療用置換ピラジノン化合物 | |
JP2004509097A (ja) | 酸化窒素シンターゼ阻害剤として有用な2−アミノ−2−アルキル−4ヘキセン酸及びヘキシン酸誘導体 | |
JP2003530435A (ja) | 一酸化窒素シンターゼ阻害剤として有用なハロゲン化2−アミノ−5,6−ヘプテン酸誘導体 | |
MXPA06004498A (es) | Compuestos de pirimidina para el tratamiento de inflamacion. | |
JP2003531132A (ja) | 一酸化窒素シンターゼ阻害剤として有用なハロゲン化2−アミノ−4,5−ヘプテン酸誘導体 | |
KR20100072090A (ko) | 5-lo 억제제로서의 피라졸 유도체 | |
JP2003530412A (ja) | 一酸化窒素シンターゼ阻害剤として有用なハロゲン化2−アミノ−3,4−ヘプテン酸誘導体 | |
US7772269B2 (en) | Pyrazole analogs | |
JP2004509098A (ja) | 酸化窒素シンターゼ阻害剤として有用な2−アミノ−2−アルキル−3ヘキセン酸及びヘキシン酸誘導体 | |
TW202033529A (zh) | 作為magl抑制劑之雜環螺環化合物 | |
EP1065206B1 (fr) | Dérivés de tétrazolylalkyl-indole comme agents anti-inflammatoires et analgésiques | |
JP2004509095A (ja) | 酸化窒素シンターゼ阻害剤として有用な2−アミノ−2−アルキル−4ヘプテン酸およびヘプチン酸誘導体 |